Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women
Background It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on th...
Saved in:
| Published in: | Cancer Vol. 126; no. 13; pp. 2971 - 2979 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Wiley Subscription Services, Inc
01.07.2020
John Wiley and Sons Inc |
| Subjects: | |
| ISSN: | 0008-543X, 1097-0142, 1097-0142 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Background
It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on the date of death.
Methods
Among 549,091 women, covering approximately 30% of the Swedish screening‐eligible population, the authors calculated the incidence rates of 2473 breast cancers that were fatal within 10 years after diagnosis and the incidence rates of 9737 advanced breast cancers. Data regarding each breast cancer diagnosis and the cause and date of death of each breast cancer case were gathered from national Swedish registries. Tumor characteristics were collected from regional cancer centers. Aggregated data concerning invitation and participation were provided by Sectra Medical Systems AB. Incidence rates were analyzed using Poisson regression.
Results
Women who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 years (relative risk, 0.59; 95% CI, 0.51‐0.68 [P < .001]) and a 25% reduction in the rate of advanced breast cancers (relative risk, 0.75; 95% CI, 0.66‐0.84 [P < .001]).
Conclusions
Substantial reductions in the incidence rate of breast cancers that were fatal within 10 years after diagnosis and in the advanced breast cancer rate were found in this contemporaneous comparison of women participating versus those not participating in screening. These benefits appeared to be independent of recent changes in treatment regimens.
Substantial and significant reductions in the incidence rates of fatal breast cancer and advanced breast cancer with 10 years of follow‐up are observed in this analysis of greater than one‐half million Swedish women participating and not participating in breast cancer screening. These comparisons are contemporaneous, and thus are not influenced by changes in therapeutic regimens. |
|---|---|
| AbstractList | Background
It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on the date of death.
Methods
Among 549,091 women, covering approximately 30% of the Swedish screening‐eligible population, the authors calculated the incidence rates of 2473 breast cancers that were fatal within 10 years after diagnosis and the incidence rates of 9737 advanced breast cancers. Data regarding each breast cancer diagnosis and the cause and date of death of each breast cancer case were gathered from national Swedish registries. Tumor characteristics were collected from regional cancer centers. Aggregated data concerning invitation and participation were provided by Sectra Medical Systems AB. Incidence rates were analyzed using Poisson regression.
Results
Women who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 years (relative risk, 0.59; 95% CI, 0.51‐0.68 [P < .001]) and a 25% reduction in the rate of advanced breast cancers (relative risk, 0.75; 95% CI, 0.66‐0.84 [P < .001]).
Conclusions
Substantial reductions in the incidence rate of breast cancers that were fatal within 10 years after diagnosis and in the advanced breast cancer rate were found in this contemporaneous comparison of women participating versus those not participating in screening. These benefits appeared to be independent of recent changes in treatment regimens.
Substantial and significant reductions in the incidence rates of fatal breast cancer and advanced breast cancer with 10 years of follow‐up are observed in this analysis of greater than one‐half million Swedish women participating and not participating in breast cancer screening. These comparisons are contemporaneous, and thus are not influenced by changes in therapeutic regimens. Substantial and significant reductions in the incidence rates of fatal breast cancer and advanced breast cancer with 10 years of follow‐up are observed in this analysis of greater than one‐half million Swedish women participating and not participating in breast cancer screening. These comparisons are contemporaneous, and thus are not influenced by changes in therapeutic regimens. Background: It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on the date of death. Methods: Among 549,091 women, covering approximately 30% of the Swedish screening‐eligible population, the authors calculated the incidence rates of 2473 breast cancers that were fatal within 10 years after diagnosis and the incidence rates of 9737 advanced breast cancers. Data regarding each breast cancer diagnosis and the cause and date of death of each breast cancer case were gathered from national Swedish registries. Tumor characteristics were collected from regional cancer centers. Aggregated data concerning invitation and participation were provided by Sectra Medical Systems AB. Incidence rates were analyzed using Poisson regression. Results: Women who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 years (relative risk, 0.59; 95% CI, 0.51‐0.68 [ P < .001]) and a 25% reduction in the rate of advanced breast cancers (relative risk, 0.75; 95% CI, 0.66‐0.84 [ P < .001]). Conclusions: Substantial reductions in the incidence rate of breast cancers that were fatal within 10 years after diagnosis and in the advanced breast cancer rate were found in this contemporaneous comparison of women participating versus those not participating in screening. These benefits appeared to be independent of recent changes in treatment regimens. It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on the date of death.BACKGROUNDIt is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on the date of death.Among 549,091 women, covering approximately 30% of the Swedish screening-eligible population, the authors calculated the incidence rates of 2473 breast cancers that were fatal within 10 years after diagnosis and the incidence rates of 9737 advanced breast cancers. Data regarding each breast cancer diagnosis and the cause and date of death of each breast cancer case were gathered from national Swedish registries. Tumor characteristics were collected from regional cancer centers. Aggregated data concerning invitation and participation were provided by Sectra Medical Systems AB. Incidence rates were analyzed using Poisson regression.METHODSAmong 549,091 women, covering approximately 30% of the Swedish screening-eligible population, the authors calculated the incidence rates of 2473 breast cancers that were fatal within 10 years after diagnosis and the incidence rates of 9737 advanced breast cancers. Data regarding each breast cancer diagnosis and the cause and date of death of each breast cancer case were gathered from national Swedish registries. Tumor characteristics were collected from regional cancer centers. Aggregated data concerning invitation and participation were provided by Sectra Medical Systems AB. Incidence rates were analyzed using Poisson regression.Women who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 years (relative risk, 0.59; 95% CI, 0.51-0.68 [P < .001]) and a 25% reduction in the rate of advanced breast cancers (relative risk, 0.75; 95% CI, 0.66-0.84 [P < .001]).RESULTSWomen who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 years (relative risk, 0.59; 95% CI, 0.51-0.68 [P < .001]) and a 25% reduction in the rate of advanced breast cancers (relative risk, 0.75; 95% CI, 0.66-0.84 [P < .001]).Substantial reductions in the incidence rate of breast cancers that were fatal within 10 years after diagnosis and in the advanced breast cancer rate were found in this contemporaneous comparison of women participating versus those not participating in screening. These benefits appeared to be independent of recent changes in treatment regimens.CONCLUSIONSSubstantial reductions in the incidence rate of breast cancers that were fatal within 10 years after diagnosis and in the advanced breast cancer rate were found in this contemporaneous comparison of women participating versus those not participating in screening. These benefits appeared to be independent of recent changes in treatment regimens. BackgroundIt is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on the date of death.MethodsAmong 549,091 women, covering approximately 30% of the Swedish screening‐eligible population, the authors calculated the incidence rates of 2473 breast cancers that were fatal within 10 years after diagnosis and the incidence rates of 9737 advanced breast cancers. Data regarding each breast cancer diagnosis and the cause and date of death of each breast cancer case were gathered from national Swedish registries. Tumor characteristics were collected from regional cancer centers. Aggregated data concerning invitation and participation were provided by Sectra Medical Systems AB. Incidence rates were analyzed using Poisson regression.ResultsWomen who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 years (relative risk, 0.59; 95% CI, 0.51‐0.68 [P < .001]) and a 25% reduction in the rate of advanced breast cancers (relative risk, 0.75; 95% CI, 0.66‐0.84 [P < .001]).ConclusionsSubstantial reductions in the incidence rate of breast cancers that were fatal within 10 years after diagnosis and in the advanced breast cancer rate were found in this contemporaneous comparison of women participating versus those not participating in screening. These benefits appeared to be independent of recent changes in treatment regimens. It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on the date of death. Among 549,091 women, covering approximately 30% of the Swedish screening-eligible population, the authors calculated the incidence rates of 2473 breast cancers that were fatal within 10 years after diagnosis and the incidence rates of 9737 advanced breast cancers. Data regarding each breast cancer diagnosis and the cause and date of death of each breast cancer case were gathered from national Swedish registries. Tumor characteristics were collected from regional cancer centers. Aggregated data concerning invitation and participation were provided by Sectra Medical Systems AB. Incidence rates were analyzed using Poisson regression. Women who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 years (relative risk, 0.59; 95% CI, 0.51-0.68 [P < .001]) and a 25% reduction in the rate of advanced breast cancers (relative risk, 0.75; 95% CI, 0.66-0.84 [P < .001]). Substantial reductions in the incidence rate of breast cancers that were fatal within 10 years after diagnosis and in the advanced breast cancer rate were found in this contemporaneous comparison of women participating versus those not participating in screening. These benefits appeared to be independent of recent changes in treatment regimens. Background It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer treatment. This can be done by measuring the incidence of fatal breast cancer, which is based on the date of diagnosis and not on the date of death. Methods Among 549,091 women, covering approximately 30% of the Swedish screening-eligible population, the authors calculated the incidence rates of 2473 breast cancers that were fatal within 10 years after diagnosis and the incidence rates of 9737 advanced breast cancers. Data regarding each breast cancer diagnosis and the cause and date of death of each breast cancer case were gathered from national Swedish registries. Tumor characteristics were collected from regional cancer centers. Aggregated data concerning invitation and participation were provided by Sectra Medical Systems AB. Incidence rates were analyzed using Poisson regression. Results Women who participated in mammography screening had a statistically significant 41% reduction in their risk of dying of breast cancer within 10 years (relative risk, 0.59; 95% CI, 0.51-0.68 [P < .001]) and a 25% reduction in the rate of advanced breast cancers (relative risk, 0.75; 95% CI, 0.66-0.84 [P < .001]). Conclusions Substantial reductions in the incidence rate of breast cancers that were fatal within 10 years after diagnosis and in the advanced breast cancer rate were found in this contemporaneous comparison of women participating versus those not participating in screening. These benefits appeared to be independent of recent changes in treatment regimens. |
| Author | Ramos, Joakim Chen, Tony Hsiu‐Hsi Fann, Jean Ching‐Yuan Wallin, Hans Carlson, Stina Åkerlund, Anders Bordás, Pál Björkgren, Annika Jonsson, Håkan Ahlgren, Johan Ku, May Mei‐Sheng Epstein, Birgitta Duffy, Stephen W. Chiu, Sherry Yueh‐Hsia Frodis, Ewa Fredriksson, Irma Grundström, Helene Chen, Yu‐Ching Wu, Wendy Yi‐Ying Sundén, Per Dean, Peter B. Törnberg, Sven Öhman, Daniel Starck, Leena Azavedo, Edward Holmberg, Lars Svane, Gunilla Smith, Robert A. Sundbom, Ann Hsu, Chen‐Yang Tabár, László Chen, Sam Li‐Sheng Yen, Amy Ming‐Fang Leifland, Karin |
| AuthorAffiliation | 6 Regional Cancer Center Umeå University Umeå Sweden 15 Orebro University Hospital Orebro Sweden 2 Department of Mammography Falun Central Hospital Falun Sweden 18 Sunderby Hospital Luleå Sweden 10 Graduate Institute of Epidemiology and Preventive Medicine College of Public Health National Taiwan University Taipei City Taiwan 14 Västerås Central Hospital Västerås Sweden 20 Norrlands University Hospital Umeå Sweden 21 Regional Cancer Center, Uppsala University Hospital Uppsala Sweden 17 Karlstad Central Hospital Karlstad Sweden 9 Department of Nutrition and Health Sciences Kainan University Taoyuan City Taiwan 19 Sundsvall Hospital Sundsvall Sweden 5 Cancer Control Sciences American Cancer Society Atlanta Georgia 13 Sankt Göran Hospital Stockholm Sweden 16 Central Hospital Gavle Sweden 12 Danderyd Hospital Danderyd Sweden 22 Regional Cancer Center Stockholm-Gotland Stockholm Sweden 11 Taipei City Hospital Taipei City Taiwan 3 School of Oral Hygiene College of Oral Medicine Taipei Medical University Taip |
| AuthorAffiliation_xml | – name: 1 Centre for Cancer Prevention Department of Epidemiology, Mathematics and Statistics Wolfson Institute of Preventive Medicine, Barts and the London School of Medicine and Dentistry Queen Mary University of London London United Kingdom – name: 12 Danderyd Hospital Danderyd Sweden – name: 7 Karolinska Institute Karolinska University Hospital Stockholm Sweden – name: 2 Department of Mammography Falun Central Hospital Falun Sweden – name: 11 Taipei City Hospital Taipei City Taiwan – name: 19 Sundsvall Hospital Sundsvall Sweden – name: 13 Sankt Göran Hospital Stockholm Sweden – name: 9 Department of Nutrition and Health Sciences Kainan University Taoyuan City Taiwan – name: 8 Division of Biostatistics Institute of Preventive Medicine Chang Gung University Taoyuan City Taiwan – name: 14 Västerås Central Hospital Västerås Sweden – name: 3 School of Oral Hygiene College of Oral Medicine Taipei Medical University Taipei City Taiwan – name: 5 Cancer Control Sciences American Cancer Society Atlanta Georgia – name: 6 Regional Cancer Center Umeå University Umeå Sweden – name: 15 Orebro University Hospital Orebro Sweden – name: 21 Regional Cancer Center, Uppsala University Hospital Uppsala Sweden – name: 22 Regional Cancer Center Stockholm-Gotland Stockholm Sweden – name: 4 Diagnostic Radiology University of Turku Turku Finland – name: 18 Sunderby Hospital Luleå Sweden – name: 10 Graduate Institute of Epidemiology and Preventive Medicine College of Public Health National Taiwan University Taipei City Taiwan – name: 17 Karlstad Central Hospital Karlstad Sweden – name: 23 Uppsala University Uppsala Sweden – name: 16 Central Hospital Gavle Sweden – name: 20 Norrlands University Hospital Umeå Sweden |
| Author_xml | – sequence: 1 givenname: Stephen W. surname: Duffy fullname: Duffy, Stephen W. email: s.w.duffy@qmul.ac.uk organization: Queen Mary University of London – sequence: 2 givenname: László surname: Tabár fullname: Tabár, László organization: Falun Central Hospital – sequence: 3 givenname: Amy Ming‐Fang surname: Yen fullname: Yen, Amy Ming‐Fang organization: Taipei Medical University – sequence: 4 givenname: Peter B. surname: Dean fullname: Dean, Peter B. organization: University of Turku – sequence: 5 givenname: Robert A. orcidid: 0000-0003-3344-2238 surname: Smith fullname: Smith, Robert A. organization: American Cancer Society – sequence: 6 givenname: Håkan surname: Jonsson fullname: Jonsson, Håkan organization: Umeå University – sequence: 7 givenname: Sven surname: Törnberg fullname: Törnberg, Sven organization: Karolinska University Hospital – sequence: 8 givenname: Sam Li‐Sheng orcidid: 0000-0001-9750-3015 surname: Chen fullname: Chen, Sam Li‐Sheng organization: Taipei Medical University – sequence: 9 givenname: Sherry Yueh‐Hsia surname: Chiu fullname: Chiu, Sherry Yueh‐Hsia organization: Chang Gung University – sequence: 10 givenname: Jean Ching‐Yuan surname: Fann fullname: Fann, Jean Ching‐Yuan organization: Kainan University – sequence: 11 givenname: May Mei‐Sheng surname: Ku fullname: Ku, May Mei‐Sheng organization: National Taiwan University – sequence: 12 givenname: Wendy Yi‐Ying surname: Wu fullname: Wu, Wendy Yi‐Ying organization: Umeå University – sequence: 13 givenname: Chen‐Yang surname: Hsu fullname: Hsu, Chen‐Yang organization: National Taiwan University – sequence: 14 givenname: Yu‐Ching surname: Chen fullname: Chen, Yu‐Ching organization: Taipei City Hospital – sequence: 15 givenname: Gunilla surname: Svane fullname: Svane, Gunilla organization: Karolinska University Hospital – sequence: 16 givenname: Edward surname: Azavedo fullname: Azavedo, Edward organization: Karolinska University Hospital – sequence: 17 givenname: Helene surname: Grundström fullname: Grundström, Helene organization: Danderyd Hospital – sequence: 18 givenname: Per surname: Sundén fullname: Sundén, Per organization: Danderyd Hospital – sequence: 19 givenname: Karin surname: Leifland fullname: Leifland, Karin organization: Sankt Göran Hospital – sequence: 20 givenname: Ewa surname: Frodis fullname: Frodis, Ewa organization: Västerås Central Hospital – sequence: 21 givenname: Joakim surname: Ramos fullname: Ramos, Joakim organization: Västerås Central Hospital – sequence: 22 givenname: Birgitta surname: Epstein fullname: Epstein, Birgitta organization: Orebro University Hospital – sequence: 23 givenname: Anders surname: Åkerlund fullname: Åkerlund, Anders organization: Central Hospital – sequence: 24 givenname: Ann surname: Sundbom fullname: Sundbom, Ann organization: Karlstad Central Hospital – sequence: 25 givenname: Pál surname: Bordás fullname: Bordás, Pál organization: Sunderby Hospital – sequence: 26 givenname: Hans surname: Wallin fullname: Wallin, Hans organization: Sundsvall Hospital – sequence: 27 givenname: Leena surname: Starck fullname: Starck, Leena organization: Sundsvall Hospital – sequence: 28 givenname: Annika surname: Björkgren fullname: Björkgren, Annika organization: Norrlands University Hospital – sequence: 29 givenname: Stina surname: Carlson fullname: Carlson, Stina organization: Norrlands University Hospital – sequence: 30 givenname: Irma surname: Fredriksson fullname: Fredriksson, Irma organization: Karolinska University Hospital – sequence: 31 givenname: Johan surname: Ahlgren fullname: Ahlgren, Johan organization: Regional Cancer Center, Uppsala University Hospital – sequence: 32 givenname: Daniel surname: Öhman fullname: Öhman, Daniel organization: Stockholm-Gotland – sequence: 33 givenname: Lars surname: Holmberg fullname: Holmberg, Lars organization: Uppsala University – sequence: 34 givenname: Tony Hsiu‐Hsi orcidid: 0000-0002-5799-6705 surname: Chen fullname: Chen, Tony Hsiu‐Hsi organization: National Taiwan University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32390151$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-171337$$DView record from Swedish Publication Index (Umeå universitet) https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423766$$DView record from Swedish Publication Index (Uppsala universitet) http://kipublications.ki.se/Default.aspx?queryparsed=id:143626318$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNp9kktv1DAUhSNURKeFDT8AWWKDUFP8Shx3gVQNT6mAVAFiZznOzdQlsQc76Wj-PQ6ZAq2gG9v3-jtHV_Y5yPacd5Bljwk-JhjTF8aZcMxoVch72YJgKXJMON3LFhjjKi84-7afHcR4mUpBC_Yg22eUSUwKssjqD7rv_Sro9cUWRRMAnHUrFKAZDUQU9JBW3yLdXGlnoEHaNajVg-5QHUDHAZmpH-IJOoc4dkNE1qGCyyMsCdr4HtzD7H6ruwiPdvth9uXN68_Ld_nZp7fvl6dnuSmpkLnANasLKDVQKKSQmmnK6hJzYiipBLTYNLJqy5JwVvBKy5KaChrcCN5iRlp2mOWzb9zAeqzVOtheh63y2qpd63s6geKCcMwSf_Rf_pX9eqp8WKlxVJwyUZZ32v_B-1ERQRgTiX858wnuoTHghqC7G7KbN85eqJW_UoKR9JVVMni2Mwj-xwhxUL2NBrpOO_BjVJRjQhJa8oQ-vYVe-jG49NoTJcsCUzEZPvl7ot-jXKchAXgGTPAxBmiVsYMerJ8GtJ0iWE2BU1Pg1K_AJcnzW5Jr13_CZIY3toPtHaRaflyez5qf4ZvmHQ |
| CitedBy_id | crossref_primary_10_1016_j_jacr_2021_04_021 crossref_primary_10_1007_s11547_024_01804_z crossref_primary_10_1016_j_ejrad_2021_109661 crossref_primary_10_1016_j_breast_2023_103590 crossref_primary_10_1093_jbi_wbab039 crossref_primary_10_1080_17435889_2025_2496129 crossref_primary_10_1002_jum_15848 crossref_primary_10_7326_ANNALS_24_00720 crossref_primary_10_1016_j_pop_2024_12_007 crossref_primary_10_1007_s12687_024_00735_6 crossref_primary_10_1007_s10278_025_01613_4 crossref_primary_10_1007_s10549_022_06527_1 crossref_primary_10_1097_CEJ_0000000000000667 crossref_primary_10_1016_j_gerinurse_2023_10_019 crossref_primary_10_37549_AR2809 crossref_primary_10_1016_S1470_2045_20_30495_2 crossref_primary_10_1093_jncics_pkaf067 crossref_primary_10_1186_s13058_025_02012_x crossref_primary_10_1016_j_soc_2023_05_013 crossref_primary_10_1080_09540091_2023_2289836 crossref_primary_10_1186_s12885_023_10890_7 crossref_primary_10_3390_healthcare11060856 crossref_primary_10_1007_s12609_022_00469_9 crossref_primary_10_1007_s10552_023_01833_5 crossref_primary_10_1016_j_tjog_2023_11_012 crossref_primary_10_1007_s10549_025_07633_6 crossref_primary_10_1111_ans_18898 crossref_primary_10_1590_1413_81232023282_07742022 crossref_primary_10_3390_cancers14194831 crossref_primary_10_1038_s41591_023_02625_9 crossref_primary_10_1016_j_dialog_2025_100235 crossref_primary_10_1177_08404704251348812 crossref_primary_10_2147_CLEP_S376107 crossref_primary_10_1007_s10549_022_06828_5 crossref_primary_10_1089_pop_2023_0178 crossref_primary_10_1177_02841851251356176 crossref_primary_10_1186_s13058_025_02029_2 crossref_primary_10_3390_diagnostics15121499 crossref_primary_10_1016_j_rcl_2024_04_001 crossref_primary_10_1016_j_canep_2024_102611 crossref_primary_10_1038_s41598_025_00984_6 crossref_primary_10_1093_jbi_wbab057 crossref_primary_10_3389_fonc_2024_1518567 crossref_primary_10_53011_JMRO_2023_01_01 crossref_primary_10_1038_s41416_023_02174_5 crossref_primary_10_1093_jbi_wbac021 crossref_primary_10_7717_peerj_20058 crossref_primary_10_1016_j_bpobgyn_2021_11_007 crossref_primary_10_3389_fmed_2021_805182 crossref_primary_10_3390_cancers14174337 crossref_primary_10_3390_nu16234143 crossref_primary_10_4178_epih_e2022094 crossref_primary_10_1002_nop2_1865 crossref_primary_10_1186_s12905_024_02924_4 crossref_primary_10_3390_ijms25158506 crossref_primary_10_1177_18758592241297849 crossref_primary_10_1038_s41598_022_21616_3 crossref_primary_10_1186_s12885_022_09193_0 crossref_primary_10_3390_diagnostics12071643 crossref_primary_10_1186_s12905_024_03521_1 crossref_primary_10_1016_j_acra_2023_12_006 crossref_primary_10_3390_cancers15123069 crossref_primary_10_1093_jbi_wbab067 crossref_primary_10_1148_radiol_2021211080 crossref_primary_10_3389_fonc_2024_1413076 crossref_primary_10_1016_j_ejrad_2023_111061 crossref_primary_10_1053_j_ro_2021_12_005 crossref_primary_10_3389_fpsyt_2023_1085115 crossref_primary_10_1158_1940_6207_CAPR_20_0447 crossref_primary_10_1007_s12559_023_10189_6 crossref_primary_10_1371_journal_pone_0304757 crossref_primary_10_1093_jnci_djab055 crossref_primary_10_3390_math11234725 crossref_primary_10_3389_fonc_2025_1529907 crossref_primary_10_1093_eurpub_ckae204 crossref_primary_10_1038_s41416_021_01521_8 crossref_primary_10_1097_JNC_0000000000000563 crossref_primary_10_1016_j_clinimag_2021_06_005 crossref_primary_10_1093_jbi_wbaf030 crossref_primary_10_1007_s12262_021_03099_0 crossref_primary_10_3390_cancers16203505 crossref_primary_10_3389_fmed_2023_1276434 crossref_primary_10_1093_fampra_cmaf018 crossref_primary_10_3390_cancers17020214 crossref_primary_10_1016_j_clinimag_2021_06_011 crossref_primary_10_3390_ijms241310752 crossref_primary_10_4274_tmsj_galenos_2024_281024 crossref_primary_10_1016_j_jclinepi_2024_111426 crossref_primary_10_1177_08465371221120798 crossref_primary_10_1016_j_cancergen_2023_12_003 crossref_primary_10_1016_j_clbc_2025_08_021 crossref_primary_10_3390_jcm10215135 crossref_primary_10_1016_j_mric_2023_09_012 crossref_primary_10_1148_radiol_232286 crossref_primary_10_1055_s_0044_1788606 crossref_primary_10_1016_j_compbiomed_2025_109654 crossref_primary_10_1093_jbi_wbae090 crossref_primary_10_1177_09691413231186686 crossref_primary_10_1109_TBME_2024_3479081 crossref_primary_10_1007_s00330_025_11821_9 crossref_primary_10_3389_fpubh_2023_1171209 crossref_primary_10_3390_s21134570 crossref_primary_10_2196_62833 crossref_primary_10_1186_s12880_025_01767_1 crossref_primary_10_3390_diagnostics14121212 crossref_primary_10_1016_j_gerinurse_2025_103514 crossref_primary_10_1016_j_compbiomed_2021_104800 crossref_primary_10_1016_j_clinimag_2022_10_013 crossref_primary_10_1148_radiol_241447 crossref_primary_10_1001_jamanetworkopen_2024_58141 crossref_primary_10_1001_jamanetworkopen_2023_45530 crossref_primary_10_1016_j_jss_2024_09_067 crossref_primary_10_1016_j_ejrad_2022_110433 crossref_primary_10_1002_cam4_70543 crossref_primary_10_1016_j_amjsurg_2022_05_008 crossref_primary_10_3389_fonc_2023_1128467 crossref_primary_10_1016_S1470_2045_24_00015_9 crossref_primary_10_1007_s12609_023_00518_x crossref_primary_10_1148_radiol_232535 crossref_primary_10_1177_11782234221121001 crossref_primary_10_1002_mp_17521 crossref_primary_10_1186_s12916_023_03217_7 crossref_primary_10_1016_j_radi_2024_04_003 crossref_primary_10_1016_j_clinimag_2022_07_001 crossref_primary_10_3390_cancers13215384 crossref_primary_10_1002_cam4_6182 crossref_primary_10_1007_s11864_024_01271_8 crossref_primary_10_1093_jbi_wbae028 crossref_primary_10_1158_1940_6207_CAPR_23_0451 crossref_primary_10_7189_jogh_12_04061 crossref_primary_10_1016_j_ejmp_2023_102524 crossref_primary_10_1016_j_irbm_2022_05_004 crossref_primary_10_1016_j_clinsp_2024_100510 crossref_primary_10_2147_BCTT_S314447 crossref_primary_10_1067_j_cpradiol_2022_09_003 crossref_primary_10_1124_jpet_124_002176 crossref_primary_10_1002_hsr2_70253 crossref_primary_10_1002_cam4_3803 crossref_primary_10_1186_s13058_024_01841_6 crossref_primary_10_1007_s11042_024_20539_7 crossref_primary_10_1002_mp_17878 crossref_primary_10_1177_08465371241306737 crossref_primary_10_1093_jbi_wbae034 crossref_primary_10_1177_11782234251353270 crossref_primary_10_2196_59483 crossref_primary_10_1016_j_acra_2023_11_037 crossref_primary_10_1093_jnci_djac009 crossref_primary_10_1093_jnci_djac008 crossref_primary_10_1200_PO_25_00365 crossref_primary_10_1002_path_5902 crossref_primary_10_1016_j_breast_2022_07_004 crossref_primary_10_1007_s12262_021_03160_y crossref_primary_10_1002_advs_202500556 crossref_primary_10_1038_s41598_022_15632_6 crossref_primary_10_1186_s12905_024_03007_0 crossref_primary_10_2196_42343 crossref_primary_10_1186_s13058_023_01738_w crossref_primary_10_3389_fonc_2024_1406946 crossref_primary_10_1117_1_JMI_12_S2_S22013 crossref_primary_10_3390_diagnostics12123111 crossref_primary_10_1007_s10549_020_06020_7 crossref_primary_10_1007_s10549_025_07662_1 crossref_primary_10_1016_j_medengphy_2022_103895 crossref_primary_10_1016_j_acra_2022_04_005 crossref_primary_10_1016_j_crad_2022_11_012 crossref_primary_10_3390_ijerph18115509 crossref_primary_10_1016_j_ejrai_2025_100013 crossref_primary_10_1016_j_jacr_2022_08_011 crossref_primary_10_1016_j_cpet_2023_04_003 crossref_primary_10_1016_j_heliyon_2024_e27072 crossref_primary_10_1002_cncr_35337 crossref_primary_10_1186_s13244_020_00905_3 crossref_primary_10_3390_healthcare11040511 crossref_primary_10_3390_cancers14071756 crossref_primary_10_1007_s12262_021_02806_1 crossref_primary_10_1186_s13058_022_01581_5 crossref_primary_10_3390_ijerph18052456 crossref_primary_10_1007_s10549_025_07703_9 crossref_primary_10_1097_XCS_0000000000000548 crossref_primary_10_1007_s00432_023_04905_w crossref_primary_10_1016_j_ejrad_2022_110189 crossref_primary_10_12677_mos_2025_144363 crossref_primary_10_1093_jbi_wbac041 crossref_primary_10_1007_s11912_023_01472_8 crossref_primary_10_1007_s10549_020_06088_1 crossref_primary_10_1016_j_ejrad_2022_110605 crossref_primary_10_1016_j_breast_2022_09_007 crossref_primary_10_1177_10732748231167254 crossref_primary_10_1002_jum_16047 crossref_primary_10_1148_radiol_221797 crossref_primary_10_1016_j_cmpb_2022_106884 crossref_primary_10_1073_pnas_2122245119 crossref_primary_10_3390_jpm14010063 crossref_primary_10_1186_s12916_022_02440_y crossref_primary_10_1007_s11547_025_02065_0 crossref_primary_10_1016_j_focus_2025_100386 crossref_primary_10_1177_09691413231197131 crossref_primary_10_1186_s12905_024_02960_0 crossref_primary_10_2147_CLEP_S267584 crossref_primary_10_3390_cancers16030655 crossref_primary_10_1111_mbe_12407 crossref_primary_10_1148_rg_240128 crossref_primary_10_1007_s10549_025_07713_7 crossref_primary_10_1007_s12609_023_00473_7 crossref_primary_10_3389_fpsyg_2025_1414099 crossref_primary_10_1148_radiol_241397 crossref_primary_10_1016_j_bcp_2024_116644 crossref_primary_10_1002_cam4_71004 crossref_primary_10_1148_radiol_2021203935 crossref_primary_10_1097_XCS_0000000000000647 crossref_primary_10_1590_1806_9282_20241501 crossref_primary_10_3390_diagnostics13040708 crossref_primary_10_1007_s10549_023_07092_x crossref_primary_10_1148_radiol_2021210226 crossref_primary_10_1016_j_ejrad_2022_110394 crossref_primary_10_1016_j_ejrad_2022_110391 crossref_primary_10_1259_bjr_20230210 crossref_primary_10_1016_j_clbc_2024_09_012 crossref_primary_10_1186_s12889_023_16227_0 crossref_primary_10_1080_14737159_2020_1859370 |
| Cites_doi | 10.1093/annonc/mdq633 10.1007/s10549-012-2384-y 10.1136/jms.7.1.14 10.1002/cncr.31840 10.1038/bjc.2016.415 10.1056/NEJMoa1000727 10.2217/bmt.13.53 10.1148/radiol.11110469 10.1111/1467-9876.00266 10.1136/bmj.h4901 10.1186/s12885-018-4666-1 10.1258/jms.2012.012080 10.1258/096914107781261918 10.1002/cncr.22671 10.1158/1055-9965.EPI-05-0349 |
| ContentType | Journal Article |
| Copyright | 2020 The Authors. published by Wiley Periodicals, Inc. on behalf of American Cancer Society 2020 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. 2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2020 The Authors. published by Wiley Periodicals, Inc. on behalf of American Cancer Society – notice: 2020 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. – notice: 2020. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM ADHXS ADTPV AOWAS D8T D93 ZZAVC ACNBI DF2 |
| DOI | 10.1002/cncr.32859 |
| DatabaseName | Wiley Online Library Open Access CrossRef PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Umeå universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Umeå universitet SwePub Articles full text SWEPUB Uppsala universitet full text SWEPUB Uppsala universitet |
| DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts PubMed |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Mammography and fatal breast cancers |
| EISSN | 1097-0142 |
| EndPage | 2979 |
| ExternalDocumentID | oai_swepub_ki_se_471403 oai_DiVA_org_uu_423766 oai_DiVA_org_umu_171337 PMC7318598 32390151 10_1002_cncr_32859 CNCR32859 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: American Cancer Society funderid: Project NHPDCSGBR‐GBRLONG – fundername: Bröstcancerförbundet, Sweden – fundername: American Cancer Society grantid: Project NHPDCSGBR-GBRLONG – fundername: ; grantid: Project NHPDCSGBR‐GBRLONG |
| GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AARRQ AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EMOBN EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ .Y3 31~ 3O- AAMMB AAQOH AAYXX AEFGJ AEYWJ AFFNX AGHNM AGNAY AGXDD AGYGG AI. AIDQK AIDYY C1A CITATION EJD HF~ H~9 J5H LW6 N4W NEJ O8X OHT RSU VH1 WHG Y6R YQJ ZXP NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 5PM ADHXS ADTPV AOWAS D8T D93 ZZAVC ACNBI DF2 |
| ID | FETCH-LOGICAL-c6279-70b3b5e6ae2e5979a3a23b6041c2187ef0cd98f66143548a962c8ed0d74f031f3 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 253 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000531341900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0008-543X 1097-0142 |
| IngestDate | Tue Nov 25 03:34:02 EST 2025 Tue Nov 04 16:38:09 EST 2025 Tue Nov 04 16:38:57 EST 2025 Tue Sep 30 16:56:11 EDT 2025 Sat Sep 27 22:04:48 EDT 2025 Tue Oct 07 06:46:12 EDT 2025 Thu Apr 03 07:02:13 EDT 2025 Sat Nov 29 07:00:36 EST 2025 Tue Nov 18 22:42:34 EST 2025 Wed Jan 22 16:33:29 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 13 |
| Keywords | mortality breast cancer screening fatality mammography |
| Language | English |
| License | Attribution-NonCommercial-NoDerivs 2020 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c6279-70b3b5e6ae2e5979a3a23b6041c2187ef0cd98f66143548a962c8ed0d74f031f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Special thanks are due to Sectra Medical Systems AB of Linkoping, Sweden, for painstaking informatics and the provision of essential population screening data. We also thank the women who participated in the screening and the staff of all the screening centers involved. Stephen W. Duffy, László Tabár, Lars Holmberg, and Tony Hsiu‐Hsi Chen contributed equally to this article. |
| ORCID | 0000-0001-9750-3015 0000-0002-5799-6705 0000-0003-3344-2238 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.32859 |
| PMID | 32390151 |
| PQID | 2409650278 |
| PQPubID | 2045183 |
| PageCount | 9 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_471403 swepub_primary_oai_DiVA_org_uu_423766 swepub_primary_oai_DiVA_org_umu_171337 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7318598 proquest_miscellaneous_2401118564 proquest_journals_2409650278 pubmed_primary_32390151 crossref_citationtrail_10_1002_cncr_32859 crossref_primary_10_1002_cncr_32859 wiley_primary_10_1002_cncr_32859_CNCR32859 |
| PublicationCentury | 2000 |
| PublicationDate | July 1, 2020 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: July 1, 2020 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Atlanta – name: Hoboken |
| PublicationTitle | Cancer |
| PublicationTitleAlternate | Cancer |
| PublicationYear | 2020 |
| Publisher | Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
| References | 2018; 18 2013; 2 2002; 51 2013; 137 2006; 15 2000; 7 2015; 351 1987 2010; 363 2011; 22 2012; 19 2019; 125 2011; 260 2007; 109 2016; 15 2007; 14 2017; 116 e_1_2_8_17_1 e_1_2_8_18_1 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 IARC Working Group on the Evaluation of Cancer‐Preventive Strategies (e_1_2_8_3_1) 2016 e_1_2_8_16_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 Breslow NE (e_1_2_8_8_1) 1987 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_12_1 |
| References_xml | – volume: 15 start-page: 45 year: 2006 end-page: 51 article-title: Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data publication-title: Cancer Epidemiol Biomarkers Prev – volume: 51 start-page: 234 year: 2002 end-page: 243 article-title: Correcting for non‐compliance bias in case‐control studies to evaluate cancer screening programs publication-title: J R Stat Soc Ser C Appl Stat – volume: 2 start-page: 519 year: 2013 end-page: 528 article-title: Real and artificial controversies in breast cancer screening: a perspective article publication-title: Breast Cancer Manag – volume: 125 start-page: 515 year: 2019 end-page: 523 article-title: The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening publication-title: Cancer – year: 1987 – volume: 22 start-page: 1726 year: 2011 end-page: 1735 article-title: Advanced breast cancer incidence following population‐based mammographic screening publication-title: Ann Oncol – volume: 15 year: 2016 – volume: 137 start-page: 653 year: 2013 end-page: 663 article-title: Reduction in rate of node metastases with breast screening: consistency of association with tumor size publication-title: Breast Cancer Res Treat – volume: 19 start-page: 33 issue: suppl 1 year: 2012 end-page: 41 article-title: Breast cancer mortality in mammographic screening in Europe: a review of incidence‐based mortality studies publication-title: J Med Screen – volume: 14 start-page: 87 year: 2007 end-page: 93 article-title: Service screening with mammography in Northern Sweden: effects on breast cancer mortality–an update publication-title: J Med Screen – volume: 7 start-page: 14 year: 2000 end-page: 18 article-title: Implementation of service screening with mammography in Sweden: from pilot study to nationwide programme publication-title: J Med Screen – volume: 351 year: 2015 article-title: Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients publication-title: BMJ – volume: 363 start-page: 1203 year: 2010 end-page: 1210 article-title: Effect of screening mammography on breast‐cancer mortality in Norway publication-title: N Engl J Med – volume: 260 start-page: 658 year: 2011 end-page: 663 article-title: Swedish two‐county trial: impact of mammographic screening on breast cancer mortality during 3 decades publication-title: Radiology – volume: 116 start-page: 246 year: 2017 end-page: 252 article-title: Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: an individual‐level cohort study publication-title: Br J Cancer – volume: 18 start-page: 860 year: 2018 article-title: The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review publication-title: BMC Cancer – volume: 109 start-page: 2205 year: 2007 end-page: 2212 article-title: Effect of mammographic service screening on stage at presentation of breast cancers in Sweden publication-title: Cancer – ident: e_1_2_8_15_1 doi: 10.1093/annonc/mdq633 – ident: e_1_2_8_14_1 doi: 10.1007/s10549-012-2384-y – ident: e_1_2_8_7_1 doi: 10.1136/jms.7.1.14 – ident: e_1_2_8_6_1 doi: 10.1002/cncr.31840 – ident: e_1_2_8_11_1 doi: 10.1038/bjc.2016.415 – volume-title: Statistical Methods in Cancer Research Volume II: The Design and Analysis of Cohort Studies year: 1987 ident: e_1_2_8_8_1 – ident: e_1_2_8_13_1 doi: 10.1056/NEJMoa1000727 – ident: e_1_2_8_17_1 doi: 10.2217/bmt.13.53 – ident: e_1_2_8_2_1 doi: 10.1148/radiol.11110469 – ident: e_1_2_8_10_1 doi: 10.1111/1467-9876.00266 – ident: e_1_2_8_18_1 doi: 10.1136/bmj.h4901 – ident: e_1_2_8_16_1 doi: 10.1186/s12885-018-4666-1 – ident: e_1_2_8_5_1 doi: 10.1258/jms.2012.012080 – ident: e_1_2_8_9_1 doi: 10.1258/096914107781261918 – ident: e_1_2_8_12_1 doi: 10.1002/cncr.22671 – volume-title: Breast Cancer Screening year: 2016 ident: e_1_2_8_3_1 – ident: e_1_2_8_4_1 doi: 10.1158/1055-9965.EPI-05-0349 |
| SSID | ssj0007253 |
| Score | 2.6918468 |
| Snippet | Background
It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in... Substantial and significant reductions in the incidence rates of fatal breast cancer and advanced breast cancer with 10 years of follow‐up are observed in this... It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast cancer... BackgroundIt is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in breast... Background: It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in... Background It is of paramount importance to evaluate the impact of participation in organized mammography service screening independently from changes in... |
| SourceID | swepub pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2971 |
| SubjectTerms | Approximation Breast cancer Diagnosis fatality Health risk assessment Health risks Mammography mortality Oncology Original Reduction Regression analysis Risk screening Statistical analysis |
| Title | Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.32859 https://www.ncbi.nlm.nih.gov/pubmed/32390151 https://www.proquest.com/docview/2409650278 https://www.proquest.com/docview/2401118564 https://pubmed.ncbi.nlm.nih.gov/PMC7318598 https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-171337 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-423766 http://kipublications.ki.se/Default.aspx?queryparsed=id:143626318 |
| Volume | 126 |
| WOSCitedRecordID | wos000531341900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 1097-0142 dateEnd: 20241207 omitProxy: false ssIdentifier: ssj0007253 issn: 1097-0142 databaseCode: WIN dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1097-0142 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0007253 issn: 1097-0142 databaseCode: DRFUL dateStart: 19960101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-NDaG98M0IjMmIDwlEWGI7sYN4mToqkLZqqhjrm5U4NlSMFCUNfz9nJ81UbZqEeImc-JIozp3v5_P5Z4CX1kS8KKkJY6bLkFujwyyjeYjewvLSAdjULxQ-EpOJnM2ykw34uFoL0_FDDAE3Zxm-v3YGnhfN_gVpqK50_Z45_rUbsBXHTLqNGyg_GfphQXsOykiGCWezgZyU7l_cu-6OLmHMy6mSPaHoOpb1zmh85_8-4y7c7kEoOei05h5smOo-3Drup9kfQHGco3p2XNYE-xUc66KHI7WjeTUNcewSDVlYskogIHlVEusCQaRwSe5Lot31uvlApqZpz5cNmVcEx4jvEDcQT_rwEE7Hn76OPof9ZgyhTqnIQhEVrEhMmhtqcBCS5SynrEgjHmtECcLYSJeZtM7dMxwF5VlKtTRlVApuseOw7BFsVovKPAYiU4QdhS60Thi3WKCxTUwitdulPZEigDerf6J0z1TuNsw4Vx3HMlWu0ZRvtABeDLK_O36OK6V2V79W9TbaKMQyGeJTKmQAz4dqtC43ZZJXZtF6GXQGMkl5ADudJgyvYdTHi-IAxJqODAKOuXu9ppr_8Azewq1Zz_C9rzttWrvlcP7tQC3q76r91arYBRGwRV5dK9gqn92UXv3A_tJPLBnFPUNjAG-9Ul7TZmo0GU196cm_CD-FbepCEj6jeRc2l3VrnsFN_Wc5b-o9b6F4FDO5B1uH0_HpEZ6dfZn8Bec9RIg |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Zb9QwEB5BQcAL9xEoYMQhgQhNbOfirVqoWrEboarAvlmJY8OKkkXJht_PjJNNtWpVCfFmOZNEcWY834zHnwFeWBPIsuLGD4WufGmN9rOMFz56CysrArCx2yg8TfI8nc-zz0NtDu2F6fkhxoQbWYabr8nAKSG9c8IaqmvdvBNEwHYRLklEGnRyw7eDfJyIEz6QUAapH0kxH9lJ-c7JvZv-6BTIPF0rOTCKboJZ5432bvznd9yE6wMMZbu93tyCC6a-DVdmw0L7HShnBSpoz2bNcGbBaBd9HGuI6NW0jPglWra0bF1CwIq6YpZSQaykMvcV09TftO_ZoWm741XLFjXDKPEtIgfmaB_uwpe9j0eTfX84jsHXMU8yPwlKUUYmLgw3GIZkhSi4KONAhhpxQmJsoKssteTwBcZBRRZznZoqqBJpceqw4h5s1cvaPACWxgg8Sl1qHQlpscFDG5ko1XROe5QmHrxe_xSlB65yOjLjWPUsy1zRoCk3aB48H2V_9wwdZ0ptr_-tGqy0VYhmMtQbnqQePBsvo33RoklRm2XnZNAdpFEsPbjfq8L4GsFdxij0INlQklGAuLs3r9SLH47DO6Fd6xm-91WvThu3fFh83VXL5rvqfnUqpDQCjsjLcwU75eqb4rMfOHT9xJZR0nE0evDGaeU5Y6Ym-eTQtR7-i_BTuLp_NJuq6UH-6RFc45SgcPXN27C1ajrzGC7rP6tF2zxx5voXf5pFSQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED9BhyZe-P4IDDDiQwIRlthOnPA2tVQgumqq2NQ3K3FsqBjplDT8_ZydNFO0aRLizYovsWLf-X4-n38GeG10wPOCaj9kqvC50cpPU5r56C0MLyyAjd1B4ZmYz5PlMj3qcnPsWZiWH6IPuFnLcPO1NXB9Vpj9c9ZQVarqI7MEbNdhh9tbZEawM1lMj2f9VCxoR0MZJH7E2bLnJ6X7528PPdIFmHkxW7LjFB3CWeePprf_80_uwK0OiJKDVnPuwjVd3oPdw26r_T7khxmqaMtnTXBuwfUuejlSWapXXRPLMFGTtSHbJAKSlQUxNhhEcpvoviHKPq_qT2Sh6-Z0U5NVSXCd-AGxA3HEDw_gePr5-_iL313I4KuYitQXQc7ySMeZphoXImnGMsryOOChQqQgtAlUkSbGunyGK6EMh0QluggKwQ1OHoY9hFG5LvVjIEmM0CNXuVIR4wYLNDSRjhJlb2qPEuHBu-2gSNWxldtLM05ly7NMpe006TrNg1e97FnL0XGp1N52bGVnp7VEPJMiRqUi8eBlX40WZrdNslKvGyeDDiGJYu7Bo1YV-mYYdTGj0AMxUJJewLJ3D2vK1U_H4i3sufUU233bqtPglcnq5ECuqx-y-d3I0AYSsEfeXCnYSJfhFF_-we7RLyxpyR1LowfvnVZe0WdyPB8vXOnJvwi_gN2jyVTOvs6_PYWb1EYoXILzHow2VaOfwQ31Z7Oqq-edvf4FvVtF8g |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mammography+screening+reduces+rates+of+advanced+and+fatal+breast+cancers&rft.jtitle=Cancer&rft.au=Duffy%2C+Stephen+W.&rft.au=Tabar%2C+Laszlo&rft.au=Yen%2C+Amy+Ming-Fang&rft.au=Dean%2C+Peter+B.&rft.date=2020-07-01&rft.issn=1097-0142&rft.volume=126&rft.issue=13&rft.spage=2971&rft_id=info:doi/10.1002%2Fcncr.32859&rft.externalDocID=oai_DiVA_org_uu_423766 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |